1385 West 8th Avenue
About Zymeworks Inc
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, Daiichi-Sankyo, Johnson & Johnson, Leo Pharma and BeiGene and is committed to making a meaningful difference in the lives of patients everywhere.
118 articles with Zymeworks Inc
Ms. O'Driscoll brings over 20 years of experience as an executive-level human resources leader across large global organizations in the technology and non-profit sectors.
Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress
Zymeworks Inc. announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer, colorectal cancer, gynecological cancers, and gastroesophageal adenocarcinoma, in a poster discussion presentation at the ESMO 2019 Congress, taking place September 27 - October 1 in Barcelona, Spain.
Zymeworks Inc. announced that Lota Zoth has been appointed as its Chair of the Board of Directors.
Trianni, Inc. ("TRIANNI") announced today that it has entered into a license agreement with Zymeworks Inc. ("ZYMEWORKS") for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support ZYMEWORKS' therapeutic discovery programs.
Zymeworks Inc. announced that management will participate in three upcoming investor conferences.
Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks
First of ten potential products built on Zymeworks’ proprietary AzymetricTM platform Zymeworks to receive US$7.5 million commercial license payment
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares
The Company intends to use the net proceeds of the Offering to accelerate and expand the global development of ZW25 both as a single agent and in combination with other anti-cancer agents in a variety of HER2-expressing tumors
Zymeworks Inc. announced the pricing of its previously-announced underwritten public offering of 5,555,556 common shares and, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares.
Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants
Zymeworks Inc. has filed a preliminary prospectus supplement to its Canadian short form base shelf prospectus dated March 6, 2019 in connection with an offering of its common shares and pre-funded warrants to purchase its common shares.
6/7/2019Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
The FDA’s Fast Track designation is designed to facilitate development and expedite the review of therapies to treat a serious diseases where there is a significant unmet medical need.
Zymeworks Inc. announced that it has earned a milestone payment from Merck achieved under the companies’ 2014 research and license agreement.
Zymeworks Inc. announced that management will present at the upcoming Jefferies 2019 Global Healthcare Conference taking place June 4-7, 2019 in New York, NY.
Zymeworks Inc. announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships.
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas.
5/16/2019Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.
Today reported financial results for the first quarter ended March 31, 2019.
Zymeworks Inc. announced it has expanded its leadership team with the hiring of three new vice presidents to support the Company’s expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and Bruce Hart, Ph.D., Vice President, Regulatory Affairs.
Zymeworks Inc. announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place April 30-May 1, 2019 in Toronto, Canada.